Skip to main content

menu

Home
About Us
- Company
- Team
- Investors
- Partners
Our Science
Clinical Development
News
Contact

MYR Pharma

From HDV control to HBV cure

Home
About Us
- Company
- Team
- Investors
- Partners
Our Science
Clinical Development
News
Contact

Pipeline

Search form

HomeClinical DevelopmentPipeline

HomeClinical DevelopmentPipeline

About

MYR GmbH is focused on development of Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection. Myrcludex B inhibits the essential HBV receptor and prevents spread of HBV in the liver. HDV is using HBV envelope to infect liver cells and may be targeted by Myrcludex B either. The product has a landscape-changing potential in both indications.

latest news

23Mar, 16

Maxwell Biotech Venture Fund’s...

01Oct, 14

Press Release, Moscow, October, 2014

Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with...

11Mar, 14

Press Release, Moscow, March 11th,...

MAXWELL BIOTECH VENTURE FUND’S PORTFOLIO COMPANY HEPATERA COMPLETES ENROLLMENT OF PHASE IIA...

15Mar, 12

Press Release, Moscow, March 15th,...

Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program

Co-Invests with...

Main menu

Home
About Us
Research And Development
Media
Contact

Contacts

Eiermarkt 3c, 30938 Burgwedel, Germany

© 2015 by MYR Pharma.

Home
About
Contact